Dacomitinib & cemiplimab's respective FDA-approvals are discussed followed by a lightning-round review of 4 immunotherapy studies from the last week. We end with dosing updates for 2 multiple myeloma drugs.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
